Skip to content
Adakveo(crizanlizumab)
Adakveo (crizanlizumab) is an antibody pharmaceutical. Crizanlizumab was first approved as Adakveo on 2019-11-15. It has been approved in Europe to treat sickle cell anemia. It is known to target P-selectin.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
Adakveo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Crizanlizumab
Tradename
Proper name
Company
Number
Date
Products
Adakveocrizanlizumab-tmcaNovartis Pharmaceuticals CorporationN-761128 RX2019-11-15
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
adakveoBiologic Licensing Application2020-06-22
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
crizanlizumab, Adakveo, Novartis Pharmaceuticals Corporation
2026-11-15Orphan excl.
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B06: Other hematological agents in atc
— B06A: Other hematological agents in atc
— B06AX: Other hematological agents in atc
— B06AX01: Crizanlizumab
HCPCS
Code
Description
J0791
Injection, crizanlizumab-tmca, 5 mg
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sickle cell anemiaD000755EFO_0000697D571412411
Covid-19D000086382U07.1—1—1—2
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukoencephalopathiesD056784HP_0002352R90.82—1———1
Primary myelofibrosisD055728D47.411———1
PriapismD011317HP_0200023N48.3—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCRIZANLIZUMAB
INNcrizanlizumab
Description
Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. It is given by injection into a vein.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4297734
ChEBI ID—
PubChem CID—
DrugBankDB15271
UNII IDL7451S9126 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SELP
SELP
Organism
Homo sapiens
Gene name
SELP
Gene synonyms
GMRP, GRMP
NCBI Gene ID
6403
Protein name
P-selectin
Protein synonyms
CD62 antigen-like family member P, CD62P, GMP-140, Granule membrane protein 140, granule membrane protein 140kDa, granulocyte membrane protein, LECAM3, Leukocyte-endothelial cell adhesion molecule 3, PADGEM, Platelet activation dependent granule-external membrane protein, platelet alpha-granule membrane protein, selectin P (granule membrane protein 140kDa, antigen CD62)
Uniprot ID
P16109
Mouse ortholog
Selp (20344)
P-selectin (Q32MF1)
Variants
Clinical Variant
No data
Financial
Adakveo - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 560 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,161 adverse events reported
View more details